Skip to main navigation Skip to search Skip to main content

Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10

  • Bridget Charbonneau
  • , Matthew S. Block
  • , William R. Bamlet
  • , Robert A. Vierkant
  • , Kimberly R. Kalli
  • , Zachary Fogarty
  • , David N. Rider
  • , Thomas A. Sellers
  • , Shelley S. Tworoger
  • , Elizabeth Poole
  • , Harvey A. Risch
  • , Helga B. Salvesen
  • , Lambertus A. Kiemeney
  • , Laura Baglietto
  • , Graham G. Giles
  • , Gianluca Severi
  • , Britton Trabert
  • , Nicolas Wentzensen
  • , Georgia Chenevix-Trench
  • , Alice S. Whittemore
  • Weiva Sieh, Jenny Chang-Claude, Elisa V. Bandera, Irene Orlow, Kathryn Terry, Marc T. Goodman, Pamela J. Thompson, Linda S. Cook, Mary Anne Rossing, Roberta B. Ness, Steven A. Narod, Jolanta Kupryjanczyk, Karen Lu, Ralf Butzow, Thilo Dork, Tanja Pejovic, Ian Campbell, Nhu D. Le, Clareann H. Bunker, Natalia Bogdanova, Ingo B. Runnebaum, Diana Eccles, James Paul, Anna H. Wu, Simon A. Gayther, Estrid Hogdall, Florian Heitz, Stanley B. Kaye, Beth Y. Karlan, Hoda Anton-Culver, Jacek Gronwald, Claus K. Hogdall, Diether Lambrechts, Peter A. Fasching, Usha Menon, Joellen Schildkraut, Celeste Leigh Pearce, Douglas A. Levine, Susanne Kruger Kjaer, Daniel Cramer, James M. Flanagan, Catherine M. Phelan, Robert Brown, Leon F.A.G. Massuger, Honglin Song, Jennifer A. Doherty, Camilla Krakstad, Dong Liang, Kunle Odunsi, Andrew Berchuck, Allan Jensen, Jan Lubinski, Heli Nevanlinna, Yukie T. Bean, Galina Lurie, Argyrios Ziogas, Christine Walsh, Evelyn Despierre, Louise Brinton, Alexander Hein, Anja Rudolph, Agnieszka Dansonka-Mieszkowska, Sara H. Olson, Philipp Harter, Jonathan Tyrer, Allison F. Vitonis, Angela Brooks-Wilson, Katja K. Aben, Malcolm C. Pike, Susan J. Ramus, Elisabeth Wik, Cezary Cybulski, Jie Lin, Lara Sucheston, Robert Edwards, Valerie McGuire, Jenny Lester, Andreas Du Bois, Lene Lundvall, Shan Wang-Gohrke, Lukasz M. Szafron, Sandrina Lambrechts, Hannah Yang, Matthias W. Beckmann, Liisa M. Pelttari, Anne M. Van Altena, David Van Den Berg, Mari K. Halle, Aleksandra Gentry-Maharaj, Ira Schwaab, Urmila Chandran, Janusz Menkiszak, Arif B. Ekici, Lynne R. Wilkens, Arto Leminen, Francesmary Modugno, Grace Friel, Joseph H. Rothstein, Ignace Vergote, Montserrat Garcia-Closas, Michelle A.T. Hildebrandt, Piotr Sobiczewski, Linda E. Kelemen, Paul D.P. Pharoah, Kirsten Moysich, Keith L. Knutson, Julie M. Cunningham, Brooke L. Fridley, Ellen L. Goode
  • Mayo Clinic Rochester, MN
  • Moffitt Cancer Center
  • Harvard University
  • Yale University
  • University of Bergen
  • Radboud University Nijmegen
  • Comprehensive Cancer Center the Netherlands
  • Cancer Council Victoria
  • Centre for Molecular, Environmental, Genetic and Analytical Epidemiology
  • Monash University
  • National Institutes of Health
  • Peter Maccallum Cancer Centre
  • Queensland Institute of Medical Research
  • Stanford University
  • German Cancer Research Center
  • The State University of New Jersey
  • Department of Epidemiology and Biostatistics
  • Cedars-Sinai Medical Center
  • University of New Mexico
  • Fred Hutchinson Cancer Research Center
  • University of Washington
  • University of Texas Health Science Center at Houston
  • University of Toronto
  • Department of Pathology
  • Department of Gynecologic Oncology
  • Helsinki University Hospital
  • Hannover Medical School
  • Oregon Health and Science University
  • University of Melbourne
  • Provincial Health Services Authority
  • University of Pittsburgh
  • Friedrich Schiller University Jena
  • University Hospital Southampton NHS Foundation Trust
  • Beatson Oncology Centre
  • University of Southern California
  • Danish Cancer Society
  • University of Copenhagen
  • Dr. Horst Schmidt Klinik GmbH
  • Kliniken Essen-Mitte
  • The Institute of Cancer Research
  • University of California at Irvine
  • International Hereditary Cancer Center
  • Flanders Institute for Biotechnology
  • KU Leuven
  • University of California at Los Angeles
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Gynaecological Cancer Research Centre
  • Institute for Women's Health
  • University College London
  • Duke University
  • Memorial Sloan-Kettering Cancer Center
  • Imperial College London
  • University of Cambridge
  • Dartmouth College
  • Texas Southern University
  • Roswell Park Cancer Institute
  • University of Hawai'i at Mānoa
  • Simon Fraser University
  • University of Texas MD Anderson Cancer Center
  • Ulm University
  • Institut für Humangenetik Wiesbaden
  • Pomeranian Medical University in Szczecin
  • Breakthrough Breast Cancer Research Centre
  • Maria Sklodowska-Curie Institute of Oncology
  • Alberta Health Services
  • University of Calgary
  • University of Kansas

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. Interleukin-1a (IL1A) is both regulated by and able to activate NF-kB, a transcription factor family that induces transcription of many proinflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged SNPs in more than 200 genes in the NF-kB pathway for a total of 2,282 SNPs (including rs17561) for genotype analysis of 15,604 cases of ovarian cancer in patients of European descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studies in the Ovarian Cancer Association Consortium. In this large population, we confirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence interval (CI), 0.76-0.93; P < 0.00075], which remained intact even after excluding participants in the prior study (OR, 0.85; 95% CI, 0.75-0.95; P < 0.006). Considering a multiple-testing-corrected significance threshold of P < 2.5 ± 10-5, only one other variant, the TNFSF10 SNP rs6785617, was associated significantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79-0.91; P < 0.00002). Our results extend the evidence that borderline tumors may have a distinct genetic etiology. Further investigation of how these SNPs might modify ovarian cancer associations with other inflammation-related risk factors is warranted.

Original languageEnglish
Pages (from-to)852-861
Number of pages10
JournalCancer Research
Volume74
Issue number3
DOIs
StatePublished - Feb 1 2014

Fingerprint

Dive into the research topics of 'Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10'. Together they form a unique fingerprint.

Cite this